A scoring system for primary biliary cirrhosis and its application for variant forms of autoimmune liver disease

2003 ◽  
Vol 38 (1) ◽  
pp. 52-59 ◽  
Author(s):  
Kazuhide Yamamoto ◽  
Ryo Terada ◽  
Ryoichi Okamoto ◽  
Youichi Hiasa ◽  
Masanori Abe ◽  
...  
Keyword(s):  
Liver Disease ◽  
Primary Biliary Cirrhosis ◽  
Scoring System ◽  
Autoimmune Liver Disease ◽  
Biliary Cirrhosis

scholarly journals Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis

2012 ◽  
Vol 11 (1) ◽  
pp. 7-14 ◽  
Author(s):  
Daniel S. Smyk ◽  
Eirini I. Rigopoulou ◽  
Luigi Muratori ◽  
Andrew K. Burroughs ◽  
Dimitrios P. Bogdanos
Keyword(s):  
Risk Factor ◽  
Liver Disease ◽  
Primary Biliary Cirrhosis ◽  
Autoimmune Liver Disease ◽  
Biliary Cirrhosis

Adjuvant Therapy for Primary Breast Cancer in a Female Patient Affected by Autoimmune Liver Disease: Does it Cure Breast Cancer and Primary Biliary Cirrhosis?

1992 ◽  
Vol 78 (6) ◽  
pp. 395-396
Author(s):  
Diana Crivellari ◽  
Renato Cannizzaro ◽  
Enzo Galligioni ◽  
Maurizio Valentini ◽  
Silvio Monfardini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Disease ◽  
Primary Biliary Cirrhosis ◽  
Liver Function ◽  
Female Patient ◽  
Autoimmune Liver Disease ◽  
Biliary Cirrhosis ◽  
Breast Cancer Patients ◽  
Biochemical Tests ◽  
Premenopausal Breast Cancer

Polychemotherapy (CMF or CMF-like regimens) is the treatment of choice in premenopausal breast cancer patients with 1–3 positive nodes. In clinical practice, patients with abnormal biochemical tests of liver function are usually excluded from this potentially curative methotrexate-containing regimen in order to avoid worsening of hepatic damage. On the other hand, recent reports have shown a beneficial effect of methotrexate in a particular autoimmune liver disease such as primary biliary cirrhosis. We discuss the case of a female patient with breast cancer and primary biliary cirrhosis whose biochemical tests of liver function and the titer of antimitochondrial antibody persistently improved after treatment with 3 cycles of CMF. In conclusion, we suggest that the CMF regimen is potentially useful in patients with breast cancer and primary biliary cirrhosis.

Apoptosis-associated antigens recognized by autoantibodies in patients with the autoimmune liver disease primary biliary cirrhosis

APOPTOSIS ◽  
2007 ◽  
Vol 13 (1) ◽  
pp. 63-75 ◽  
Author(s):  
Christoph Peter Berg ◽  
Gerburg Maria Stein ◽  
Hildegard Keppeler ◽  
Michael Gregor ◽  
Sebastian Wesselborg ◽  
...  
Keyword(s):  
Liver Disease ◽  
Primary Biliary Cirrhosis ◽  
Autoimmune Liver Disease ◽  
Biliary Cirrhosis

Prevalence of Autoimmune Liver Disease Related Autoantibodies in Chinese Patients with Primary Biliary Cirrhosis

2011 ◽  
Vol 56 (11) ◽  
pp. 3357-3363 ◽  
Author(s):  
Chaojun Hu ◽  
Chuiwen Deng ◽  
Guang Song ◽  
Wen Zhang ◽  
Shulan Zhang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Primary Biliary Cirrhosis ◽  
Autoimmune Liver Disease ◽  
Chinese Patients ◽  
Biliary Cirrhosis

Metabolism of vitamin D in patients with primary biliary cirrhosis and alcoholic liver disease

1985 ◽  
Vol 69 (5) ◽  
pp. 561-570 ◽  
Author(s):  
E. Barbara Mawer ◽  
H. J. Klass ◽  
T. W. Warnes ◽  
Jacqueline L. Berry
Keyword(s):  
Vitamin D ◽  
Liver Disease ◽  
Primary Biliary Cirrhosis ◽  
Alcoholic Liver Disease ◽  
Vitamin D3 ◽  
Control Group ◽  
Biliary Cirrhosis ◽  
Vitamin D2 ◽  
Dihydroxyvitamin D3 ◽  
Poor Renal Function

1. The metabolism of isotopically labelled vitamin D2 and D3 has been investigated in eight patients with primary biliary cirrhosis and in five controls. The concentration of labelled vitamin D2 was lower than that of vitamin D3 in serum of patients with primary biliary cirrhosis on days 1 and 2 after intravenous injection (P < 0.005 and P < 0.05, respectively) but no difference was seen in controls. 2. Similar amounts of labelled 25-hydroxyvitamin D2 and D3 were seen in serum of the control group; the same pattern was observed in the primary biliary cirrhosis group, and no significant differences were observed between the two groups. 3. In both control and primary biliary cirrhosis groups, the serum concentration of labelled 24,25-dihydroxyvitamin D2 exceeded that of 24,25-dihydroxyvitamin D3 (significant for controls on day 2, P < 0.02) but concentrations in the two groups were not different. 4. Concentrations of labelled 25,26-dihydroxyvitamin D3 were significantly higher than those of 25,26-dihydroxyvitamin D2 in the primary biliary cirrhosis group at all times and in the control group on days 2 and 3. Both 25,26-dihydroxyvitamin D2 and D3 were higher in the serum of patients with primary biliary cirrhosis than in controls (significant on day 1, P < 0.05). 5. Urinary excretion over days 0–3 of radioactivity from both vitamins D2 and D3 was significantly higher in the primary biliary cirrhosis group than in controls: 12.03 vs 1.80% for vitamin D2 and 8.98 vs 1.76% for vitamin D3(P < 0.005). Vitamin D2-derived urinary radioactivity in primary biliary cirrhosis correlated strongly with serum bilirubin (P = 0.005). 6. The metabolism of labelled vitamin D3 was studied in seven patients with alcoholic liver disease, three of whom showed low serum concentrations of labelled 25-hydroxyvitamin D3 suggesting impaired hepatic synthesis. The 25-hydroxylation response was quantified as the relative index of 25-hydroxylation and was significantly related to two other indices of liver function. It is concluded that impaired 25-hydroxylation of vitamin D may occur in alcoholic liver disease and results from hepatocellular dysfunction. 7. Less than the predicted amounts of 1,25-dihydroxyvitamin D3 were produced in four of the seven patients with alcoholic liver disease; this defect may be attributable in part to decreased precursor 25-hydroxyvitamin D and to poor renal function.

Primary Biliary Cirrhosis

2015 ◽  
Author(s):  
Daniel S. Pratt ◽  
Lindsay Y. King
Keyword(s):  
Differential Diagnosis ◽  
Liver Disease ◽  
Primary Biliary Cirrhosis ◽  
Liver Diseases ◽  
American Association ◽  
Cholestatic Liver Disease ◽  
Biliary Cirrhosis ◽  
Common Cause ◽  
History Of

Primary biliary cirrhosis (PBC) is a progressive autoimmune disease of the liver. It is the most common cause of chronic intrahepatic cholestatic liver disease in adults. This review addresses the epidemiology, etiology and genetics, pathophysiology and pathogenesis, diagnosis, differential diagnosis, treatment, complications, and prognosis of PBC. Figures show the pathogenesis and natural history of PBC and histologic features of the four stages of PBC. Tables list diagnostic criteria for PBC via the American Association for the Study of Liver Diseases, differential diagnosis for PBC, medications used to treat PBC, secondary therapy for PBC, and follow-up of patients with PBC. This review contains 2 highly rendered figures, 5 tables, and 45 references.

scholarly journals Primary Biliary Cirrhosis Associated with Systemic Sclerosis: Diagnostic and Clinical Challenges

2011 ◽  
Vol 2011 ◽  
pp. 1-12 ◽  
Author(s):  
Cristina Rigamonti ◽  
Dimitrios P. Bogdanos ◽  
Maria G. Mytilinaiou ◽  
Daniel S. Smyk ◽  
Eirini I. Rigopoulou ◽  
...  
Keyword(s):  
Liver Disease ◽  
Systemic Sclerosis ◽  
General Population ◽  
Primary Biliary Cirrhosis ◽  
Early Identification ◽  
Case Reports ◽  
Biliary Cirrhosis ◽  
Antimitochondrial Antibodies ◽  
Favorable Prognosis ◽  
Limited Systemic Sclerosis

Patients with primary biliary cirrhosis (PBC) often have concurrent limited systemic sclerosis (SSc). Conversely, up to one-fourth of SSc patients are positive for PBC-specific antimitochondrial antibodies (AMA). The mechanisms responsible for the co-occurrence of these diseases are largely unknown. Genetic, epigenetic, environmental, and infectious factors appear to be important for the pathogenesis of the disease, but the hierarchy of events are not well defined. Patients with SSc and PBC have an increased morbidity and mortality compared with the general population, but whether the presence of both diseases in an affected individual worsens the prognosis and/or outcome of either disease is not clear. Some case reports suggested that the presence of SSc in PBC patents is associated with a more favorable prognosis of the liver disease, whereas others report an increased mortality in patients with PBC and SSc compared to patients with PBC alone. This paper discusses the features of patients with PBC-associated SSc. Our aims are to clarify some of the pathogenetic, diagnostic, and clinical challenges that are currently faced in the routine management of these patients. We also intend to provide some practical hints for practitioners that will assist in the early identification of patients with PBC-associated SSc.

Sign in / Sign up

Export Citation Format

Share Document